BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3535934)

  • 1. [Cancer of the prostate: current status of chemotherapy].
    Bollak C; Bergerat JP; Jacquemin D
    Bull Cancer; 1986; 73(1):61-4. PubMed ID: 3535934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of chemotherapy in prostate cancer. Minireview.
    Odrázka K; Vanásek J; Vaculíková M; Stejskal J; Filip S
    Neoplasma; 2000; 47(4):197-203. PubMed ID: 11043822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estramustine-based chemotherapy.
    Hudes G
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The present role of estramustine phosphate in advanced prostate cancer.
    Van Poppel H; Baert L
    Prog Clin Biol Res; 1991; 370():323-41. PubMed ID: 1924466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB; Lindner A
    Urol Clin North Am; 1984 May; 11(2):319-26. PubMed ID: 6233779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for androgen-independent prostate cancer.
    Gulley J; Figg WD; Dahut WL
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EMP combination chemotherapy and low-dose monotherapy in advanced prostate cancer.
    Kitamura T; Nishimatsu H; Hamamoto T; Tomita K; Takeuchi T; Ohta N
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):59-71. PubMed ID: 12113067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy: is it effective in treatment of prostatic cancer?
    Murphy GP
    Urology; 1984 Nov; 24(5 Suppl):41-7. PubMed ID: 6388094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemotherapy of prostatic cancer].
    Portnoĭ AS
    Vopr Onkol; 1985; 31(9):3-12. PubMed ID: 2931901
    [No Abstract]   [Full Text] [Related]  

  • 11. Chemotherapy in advanced prostate cancer.
    Beedassy A; Cardi G
    Semin Oncol; 1999 Aug; 26(4):428-38. PubMed ID: 10482185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
    J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for prostate cancer - recent progress in clinical trials.
    Kipp RT; McNeel DG
    Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
    Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advanced prostate cancer--a therapeutic dilemma?].
    Rübben H; Altwein JE
    Urologe A; 1987 Jan; 26(1):7-14. PubMed ID: 3576864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.
    Galsky MD; Small EJ; Oh WK; Chen I; Smith DC; Colevas AD; Martone L; Curley T; Delacruz A; Scher HI; Kelly WK
    J Clin Oncol; 2005 Mar; 23(7):1439-46. PubMed ID: 15735119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of hormone refractory prostate cancer: current standards and future prospects.
    Oh WK; Kantoff PW
    J Urol; 1998 Oct; 160(4):1220-9. PubMed ID: 9751323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of prostatic cancer.
    Schmidt JD
    Urol Clin North Am; 1975 Feb; 2(1):185-96. PubMed ID: 1093059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.